Time to Reconsider Luminex Corporation (LMNX) After Touching 52-Week High?

July 12, 2018 - By Robert Sims

Luminex Corporation (NASDAQ:LMNX) Logo

The stock of Luminex Corporation (NASDAQ:LMNX) hit a new 52-week high and has $33.76 target or 9.00 % above today’s $30.97 share price. The 9 months bullish chart indicates low risk for the $1.38B company. The 1-year high was reported on Jul, 12 by Barchart.com. If the $33.76 price target is reached, the company will be worth $123.93 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 0.13% or $0.04 during the last trading session, reaching $30.97. About 28,911 shares traded. Luminex Corporation (NASDAQ:LMNX) has risen 33.74% since July 12, 2017 and is uptrending. It has outperformed by 21.17% the S&P500.

Analysts await Luminex Corporation (NASDAQ:LMNX) to report earnings on August, 6. They expect $0.20 earnings per share, 0.00 % or $0.00 from last year’s $0.2 per share. LMNX’s profit will be $8.89 million for 38.71 P/E if the $0.20 EPS becomes a reality. After $0.25 actual earnings per share reported by Luminex Corporation for the previous quarter, Wall Street now forecasts -20.00 % negative EPS growth.

Another recent and important Luminex Corporation (NASDAQ:LMNX) news was published by Globenewswire.com which published an article titled: “Detailed Research: Economic Perspectives on MGM Growth Properties, Acacia Research, Luminex, Eastman …” on June 20, 2018.

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and life sciences industries worldwide. The company has market cap of $1.38 billion. The company's products include Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; Verigene system, an automated multiplex-capable system; and ARIES system, a sample to answer real-time PCR platform. It has a 40.7 P/E ratio. It also offers MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; ARIES cassettes that are self-contained assay consumables; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; respiratory viral family of products to identify the causative agent for respiratory infections; and gastrointestinal pathogen panel assays to identify the pathogens causing infectious gastroenteritis.

Luminex Corporation (NASDAQ:LMNX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: